10 completed, 5 terminated, 3 recruiting, 2 unknown. 21 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 21 | Completed 10, Terminated 5, Recruiting 3, Unknown 2, Withdrawn 1 |
Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder Acamprosate calcium, Placebo - Alcohol Use Disorder | Phase 4 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 48 | 2025-05-07 | 2026-11-02 |
| Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder Naltrexone - Alcohol Use Disorder | Phase 4 | Recruiting | Milky Kohno | 100 | 2024-05-02 | 2026-10-06 |
| Cytisine for Smoking Cessation Cytisine, Placebo - Tobacco Use Disorder, Alcohol Use Disorder | Phase 4 | Completed | Centre for Addiction and Mental Health | 20 | 2023-02-08 | 2026-02-27 |
| Naltrexone in AUD Reward Drinkers XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection - Alcohol Use Disorder, Alcoholism | Phase 4 | Recruiting | University of Pennsylvania | 60 | 2022-03-07 | 2026-01-20 |
| In Hospital IM Naltrexone: A Pilot Study injectable naltrexone, oral naltrexone - Alcohol Use Disorder | Phase 4 | Withdrawn | University of Colorado, Denver | 2022-03-01 | 2023-04-07 | |
| Bridging ED to Outpatient AUD Therapy With Naltrexone Naltrexone Pill - Alcohol Use Disorder | Phase 4 | Unknown | Albert Einstein Healthcare Network | 20 | 2022-03-01 | 2022-02-08 |
| Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder Vivitrol (Extended Release Naltrexone) - Alcohol Use Disorder, Substance Use | Phase 4 | Terminated | University of California, San Francisco | 179 | 2020-08-14 | 2023-06-22 |
| Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome Acamprosate, Placebo - Alcohol Use Disorder | Phase 4 | Completed | Mayo Clinic | 288 | 2019-07-15 | 2024-12-17 |
| Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography Beer, Videotaped drinking session - Alcohol Use Disorder | Phase 4 | Terminated | University of Florida | 11 | 2017-10-12 | 2024-12-27 |
| Topiramate Treatment of Alcohol Use Disorders in African Americans Topiramate, placebo - Alcohol Use Disorder | Phase 4 | Terminated | VA Office of Research and Development | 79 | 2017-08-01 | 2023-03-23 |
| Assessment of Valproate on Ethanol Withdrawal Valproate, Lorazepam - Alcohol Dependence, Alcohol Withdrawal Syndrome | Phase 4 | Terminated | CAMC Health System | 3 | 2017-07-11 | 2026-08-18 |
| Alcohol Disorder hOsPital Treatment Trial Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX) - Heavy Drinking, Alcohol Dependence | Phase 4 | Completed | Boston University | 248 | 2016-06-01 | 2021-06-29 |
| Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders Placebo, Citicoline, Pregnenolone - Alcohol Use Disorder, Bipolar Disorder | Phase 4 | Completed | Sherwood Brown, MD, PhD | 96 | 2016-05-01 | 2024-10-09 |
| Neural Mechanisms of Disulfiram Effects Disulfiram - Alcohol Use Disorder | Phase 4 | Completed | New York State Psychiatric Institute | 7 | 2016-03-01 | 2020-11-23 |
| Baclofen in Managing Acute Alcohol Withdrawal Diazepam 10 MG, Baclofen 30mg, Baclofen 60mg - Alcohol Use Disorder, Alcohol Withdrawal | Phase 4 | Unknown | Universitair Ziekenhuis Brussel | 90 | 2016-02-01 | 2021-11-04 |
| Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder Baclofen - Alcohol Use Disorder | Phase 4 | Terminated | University Hospital, Lille | 239 | 2015-12-24 | 2025-12-16 |
| Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users XR-NTX+CM (Extended-Release Naltrexone plus Care Management) - Alcohol Dependence, Alcohol Use Disorder | Phase 4 | Completed | NYU Langone Health | 50 | 2015-07-01 | 2022-05-11 |
| Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder oral naltrexone, Placebo pill - HIV, Alcohol Use Disorder | Phase 4 | Completed | Fred Hutchinson Cancer Center | 159 | 2014-05-01 | 2017-06-16 |
| Ondansetron for Bipolar Disorder and Alcohol Use Disorders Ondansetron, Placebo - Bipolar Disorder, Alcohol Use Disorder | Phase 4 | Completed | University of Texas Southwestern Medical Center | 70 | 2014-02-01 | 2021-08-24 |
| Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems Sertraline, Placebo - PTSD, Alcohol Use Disorder | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 49 | 2011-04-01 | 2018-04-10 |
Showing 20 of 21. Sign in to see all of them.
Alcoholism (21) · Bipolar Disorder (2) · Emergencies (2) · Substance-Related Disorders (2) · Alcohol-Related Disorders (1) · Chemically-Induced Disorders (1) · Mental Disorders (1) · Patient Acceptance of Health Care (1) · Phobia, Social (1) · Smoking Cessation (1) · Stress Disorders, Post-Traumatic (1) · Tobacco Use Disorder (1) · Wounds and Injuries (1)
Alcohol-Related Disorders (20) · Chemically-Induced Disorders (20) · Mental Disorders (20) · Substance-Related Disorders (19) · Behavior (2) · Bipolar and Related Disorders (2) · Disease Attributes (2) · Health Behavior (2) · Mood Disorders (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Anxiety Disorders (1) · Phobic Disorders (1) · Stress Disorders, Traumatic (1) · Trauma and Stressor Related Disorders (1)
Naltrexone (5) · vivitrol (4) · Acamprosate (2) · Baclofen (2) · Sugars (2) · Beer (1) · Case Management (1) · Cytidine Diphosphate Choline (1) · Diazepam (1) · Disulfiram (1) · Injections, Intramuscular (1) · Lorazepam (1) · Ondansetron (1) · Paroxetine (1) · Practice Management, Medical (1)
Albert Einstein Healthcare Network (1) · Boston University (1) · CAMC Health System (1) · Centre for Addiction and Mental Health (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · Medical University of South Carolina (1) · Milky Kohno (1) · NYU Langone Health (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · New York State Psychiatric Institute (1) · Sherwood Brown, MD, PhD (1) · The University of Texas Health Science Center at San Antonio (1) · Universitair Ziekenhuis Brussel (1) · University Hospital, Lille (1)
United States (16) · Belgium (1) · Canada (1) · France (1) · Peru (1)
Ann Duerr, MD, PhD, MPH (1) · Audis Bethea, PharmD, BCPS (1) · Bernard Le Foll (1) · Carrie L Randall, PhD (1) · Charles E Murphy IV, MD (1) · David Hui, MD (1) · David W. Oslin, MD (1) · E. Sherwood Brown, MD, PhD (1) · Frederick Altice, MD (1) · Frieda Matthys, PhD (1) · Henry R Kranzler, MD (1) · John D Roache, PhD (1) · Maria Raven, MD (1) · Nancy Diazgranados, M.D. (1) · Nasir H. Naqvi, MD, PhD (1)
PMID 10553740, PMID 11707638, PMID 1334156, PMID 1345133, PMID 1444726, PMID 15811981, PMID 16624967, PMID 17045423, PMID 18472999, PMID 23627868, PMID 24650044, PMID 24825644, PMID 25092008, PMID 26039070, PMID 26629534, PMID 28851459, PMID 29255898, PMID 32446635, PMID 33997645, PMID 34013473, PMID 34033183, PMID 35285015, PMID 3558716, PMID 36328851, PMID 40257810, PMID 8916634, PMID 9400350
2015 (1), K23AA022989 (1), R01AA013379 (1), R01AA021335 (1), R01AA027486 (1), U01AA027487 (1)